Skip to main content

Advertisement

Table 1 First reports on biochemical response following PSMA based radiotherapy after prior radical treatment of the prostate

From: PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives

Referal for salvage/ non primary radiotherapy, PSA response
Author Number of irradiated patients Treatment of Median PSA value ADT use before radiotherapy Follow up time (months) PSA response during follow up Re-Radiation ADT initiation during follow up
Henkenberens [69] 23 N, Ma, 2.75 0% 12.4 52% 26% 22%
Zschaeck [59] 20 (11) T, N, Ma, Mb 0.95 45% (0%) 29.0 70% (73%) 15% (27%) 5% (9%)
Bluemel [70] 43 T, N, Ma, Mb 0.60 0% 8.1 83%a 0% n.a.
Emmett [58] 99 T, N, Ma, Mb 0.28 0% 10.5 72% n.a. n.a.
Habl [61] 15 Mb 1.99 20% 22.5 20% 7% n.a.
Henkenberens [71] 29 T, N, Ma, Mb 1.47 38% 8.3 96% 7% 0%
Guler [68] 23 N, Ma, Mb 1.10 100% (43%b) 7.0 83% 0% 9%
  1. T = local recurrence, N = pelvic lymph nodes, Ma = extrapelvic lymph nodes, Mb = bony metastases. ADT androgen deprivation therapy
  2. aFollow up only available for 21 patients: 20 presenting good response, however 3 patients with rising PSA values during salvage irradiation were included to the non-responders (4/24 patients)
  3. b43% of patients presented with hormone refractory situation after long-term ADT